Scientists have found three new drugs that may help transform the long-term prognosis for people with the AIDS virus, thus giving hope for chronically infected patients.
The study was conducted by a team of researchers including Hiroyu Hatano, and Steven Deeks at San Francisco General Hospital, University of California, USA.
The three new drugs are the HIV integrase inhibitors, R5 inhibitors, and etravirine (TMC125), a second-generation non-nucleoside reverse transcriptase inhibitor.
HIV patients in 'deep salvage' means those people who have developed multidrug resistant HIV that does not respond to drug combination therapy.
Researchers found that HIV patients in 'deep salvage' could benefit the most from these drugs.
"Hence for patients in deep salvage, 2007 may be comparable to the landmark events of 1996, when the near miraculous effects of combination therapy were first observed," the authors wrote.
The findings of the study were published in the British Medical Journal.